Ignite Creation Date:
2024-05-05 @ 5:29 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00463021
Status:
COMPLETED
Last Update Posted:
2015-05-05
First Post:
2007-04-18
Brief Title:
A Phase 4 Study to Determine Dosing of Hectorol Capsules When Converting From Zemplar Injection
Sponsor:
Genzyme a Sanofi Company
Organization:
Sanofi
Study Overview
Official Title:
A Phase 4 Multi Center Open-Label Randomized Study to Determine Clinically Appropriate Doses of Hectorol Doxercalciferol Capsules When Converting From Zemplar Paricalcitol Injection for the Treatment of Secondary Hyperparathyroidism in Stage 5 Chronic Kidney Disease CKD Subjects on Hemodialysis
Status:
COMPLETED
Status Verified Date:
2015-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Protocol HECT00306 aims to determine clinically appropriate doses of Hectorol doxercalciferol capsules when converting from Zemplar paricalcitol injection for the treatment of secondary hyperparathyroidism in Stage 5 chronic kidney disease on hemodialysis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None